FEDERICO, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 55.684
EU - Europa 30.298
AS - Asia 19.757
SA - Sud America 3.106
AF - Africa 469
OC - Oceania 171
Continente sconosciuto - Info sul continente non disponibili 42
Totale 109.527
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 54.987
GB - Regno Unito 11.012
CN - Cina 6.325
IT - Italia 5.750
SG - Singapore 5.392
RU - Federazione Russa 3.495
HK - Hong Kong 3.006
SE - Svezia 2.554
BR - Brasile 2.517
DE - Germania 2.444
TR - Turchia 1.401
UA - Ucraina 1.401
VN - Vietnam 1.174
FI - Finlandia 843
FR - Francia 723
KR - Corea 552
BG - Bulgaria 534
JP - Giappone 371
CA - Canada 355
IN - India 307
ID - Indonesia 306
NL - Olanda 301
IE - Irlanda 250
AR - Argentina 228
AU - Australia 153
ES - Italia 143
MX - Messico 142
ZA - Sudafrica 138
BD - Bangladesh 134
BE - Belgio 130
AT - Austria 118
BZ - Belize 109
PL - Polonia 107
EC - Ecuador 91
MY - Malesia 89
IQ - Iraq 87
MA - Marocco 87
CH - Svizzera 78
RO - Romania 77
IR - Iran 75
EG - Egitto 70
CL - Cile 69
PK - Pakistan 63
CO - Colombia 60
LT - Lituania 60
SA - Arabia Saudita 59
AE - Emirati Arabi Uniti 50
TW - Taiwan 47
CZ - Repubblica Ceca 46
UZ - Uzbekistan 40
IL - Israele 38
TN - Tunisia 38
VE - Venezuela 37
KE - Kenya 33
PE - Perù 33
EU - Europa 29
NO - Norvegia 29
PY - Paraguay 28
DZ - Algeria 26
PT - Portogallo 26
TH - Thailandia 26
AZ - Azerbaigian 25
JO - Giordania 25
UY - Uruguay 24
GR - Grecia 23
NP - Nepal 22
DK - Danimarca 21
PH - Filippine 21
HU - Ungheria 18
KZ - Kazakistan 17
EE - Estonia 16
KG - Kirghizistan 16
NZ - Nuova Zelanda 15
PA - Panama 15
BO - Bolivia 13
HR - Croazia 13
LV - Lettonia 13
CR - Costa Rica 12
DO - Repubblica Dominicana 12
ET - Etiopia 12
LY - Libia 12
RS - Serbia 12
AL - Albania 11
AM - Armenia 11
LK - Sri Lanka 11
LU - Lussemburgo 10
LB - Libano 9
JM - Giamaica 8
MK - Macedonia 8
SI - Slovenia 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AO - Angola 7
BH - Bahrain 7
GE - Georgia 7
GT - Guatemala 7
HN - Honduras 7
KW - Kuwait 7
OM - Oman 7
SV - El Salvador 7
UG - Uganda 7
Totale 109.396
Salva come PNG Salva come JPEG
Città #
Southend 8.520
Fairfield 6.449
Ashburn 4.763
Santa Clara 4.630
Woodbridge 3.560
Singapore 3.349
Chandler 2.932
Hong Kong 2.930
Houston 2.916
Jacksonville 2.631
Moscow 2.572
Seattle 2.409
Wilmington 2.271
Dearborn 2.118
Cambridge 2.080
Hefei 2.032
Ann Arbor 1.639
Nyköping 1.352
London 1.279
Beijing 1.197
Los Angeles 906
Izmir 780
Chicago 761
San Diego 625
Princeton 594
Frankfurt am Main 575
Sofia 526
New York 490
Eugene 477
Modena 467
Seoul 446
Buffalo 426
Milan 387
Council Bluffs 372
Ho Chi Minh City 363
The Dalles 357
Helsinki 327
Shanghai 326
Redwood City 308
Salt Lake City 300
Rome 287
Dallas 278
Des Moines 268
Jakarta 253
San Jose 230
Columbus 227
São Paulo 224
Munich 214
Hanoi 209
Dublin 207
Dong Ket 206
Bremen 169
Tokyo 157
Boardman 146
Phoenix 144
Falls Church 143
Elk Grove Village 134
Bologna 124
Tampa 115
Norwalk 109
Belize City 106
Verona 97
Manchester 93
Guangzhou 86
San Francisco 86
Turin 86
Toronto 84
Padova 83
Brussels 80
Brooklyn 79
Philadelphia 76
Nuremberg 74
Rio de Janeiro 73
Warsaw 73
Kunming 72
Atlanta 71
Sterling 71
Turku 69
Nanjing 68
Saint Petersburg 68
Stockholm 68
Denver 66
Montreal 66
Las Vegas 65
Lancaster 64
Belo Horizonte 61
Miami 60
Paris 59
Albuquerque 58
Naples 57
San Mateo 57
Ottawa 55
Redondo Beach 55
Florence 54
Johannesburg 54
Palermo 51
Amsterdam 49
Vienna 49
Boston 48
Jinan 48
Totale 78.025
Salva come PNG Salva come JPEG
Nome #
SPLENECTOMY AFTER INITIAL THERAPY WITH ALPHA-IFN IN PATIENTS WITH HAIRY-CELL LEUKEMIA (HCL) - A MULTICENTER STUDY BY THE ITALIAN COOPERATIVE GROUP FOR HCL - PRELIMINARY-RESULTS 2.481
Hb Hasharon: studio di un nucleo familiare 1.398
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12 1.099
Eritropoiesi extramidollare intratoracica. Considerazioni clinico radiologiche su due casi di talassemia minor 1.055
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 Trial 873
Cancer profile in Eastern Libya: incidence and mortality in the year 2004. 751
Sindrome mediastinica da mieloblastoma quale manifestazione d'esordio di leucemia mieloide acuta 724
Cancer incidence in eastern Libya: The first report from the Benghazi Cancer Registry, 2003 718
Epidemiological overview of Hodgkin lymphoma across the Mediterranean Basin 716
Pattern of cancer risk in person with AIDS in Italy inthe HAART era 669
Estimates of cancer burden in Italy 644
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 624
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial 620
Risk assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. 610
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 584
IMPACT Working Group: effectiveness of service screening: a case-control study to assess breast cancer mortalità reduction. 575
Caratterizzazione morfo-funzionale delle cellule reticolari dendritiche. 516
The italian multi-center project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk 475
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 471
Il linfoma mantellare 460
T-cell lymphoma in South America and Europe. 460
Il morbo di Hodgkin sclero-nodulare. Studio clinico-patologico 457
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project 452
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 450
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 426
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 422
Nonpegylated liposomal doxorubicin (Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO 18 trial 408
Transformed follicular lymphoma 400
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 398
EUROCARE-3 summary: Cancer survival in Europe at the end of the 20th century 377
Splenic marginal zone lymphoma: a prognostic model for clinical use. 368
Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study 367
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 361
Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study. 355
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 354
Use of 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy 351
Protein expression patterns associated with advanced stage ovarian cancer 345
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 345
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. 343
Revised response criteria for malignant lymphoma. 342
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 342
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations 337
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy 335
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 332
PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract 331
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 329
Prognosis of follicular lymphomas 324
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 323
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 320
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 318
Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma - The experience of the gruppo italiano studio linfomi 318
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines 314
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma 313
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 309
Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility 309
Follicular lymphoma international prognostic index. 304
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat 303
Concordance between four European centre of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. 302
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 299
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 299
Patogenesi complessa di una emopatia sistemica: la tricoleucemia 297
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 297
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 295
Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience 294
Patologia non neoplastica del follicolo linfatico 293
Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias 293
PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study 291
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 290
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 288
Anthracyclines: A cornerstone in the management of non-Hodgkin's lymphoma 288
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study 287
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 285
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 284
Bone marrow uptake of liposome-entrapped spin label after liver blockade with empty liposomes 280
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 278
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. 276
Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature 276
Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: The Gruppo Italiano per lo Studio dei Linfomi Experience 271
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma 271
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 271
Italian family with two independent mutations:3358T/A in BRCA1 and 8756delA in BRCA2 genes. 270
Prophylactic Surgery to Reduce the Risk of Developing Breast Cancer: Issues and Clinical Implications 269
Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients 266
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 265
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 264
MRI in high risk women: benefits and problems 264
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi 263
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL) 263
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies 263
KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence 263
Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy 262
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 262
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 261
Hodgkin's disease - A quantitative evaluation by computed tomography of tumor burden 260
In situ breast cancer: Incidence trend and organised screening programmes in Italy 260
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 260
High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. 256
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 256
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry 255
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 254
Totale 41.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 412.773
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 412.773
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217.738 0 0 0 0 0 989 928 1.557 833 1.469 1.041 921
2021/202210.326 412 1.345 1.253 792 318 521 595 613 1.063 702 1.648 1.064
2022/20239.560 1.030 904 643 809 1.197 1.460 252 1.007 1.216 176 504 362
2023/20247.788 329 433 421 538 1.590 462 812 1.163 160 285 698 897
2024/202520.442 1.371 985 282 1.360 3.611 2.588 1.652 1.112 2.434 717 1.894 2.436
2025/202616.698 2.138 1.587 3.224 3.762 5.056 931 0 0 0 0 0 0
Totale 111.202